open access
Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma
open access
Abstract
Aim
Evaluate pretreatment hemoglobin values as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy.
Background
Anemia is one of the most prevalent laboratory abnormalities in oncological disease. It leads to a decrease in cellular oxygen supply, altering radiosensitivity of tumor cells and compromising therapeutic outcomes.
Materials and Methods
Retrospective evaluation of patients with HNSCC treated with cCRT. Primary and secondary endpoint was to evaluate the correlation of Hb levels (≥12.5g/dL or <12.5g/dL) at the beginning of cCRT with overall survival (OS) and progression-free survival (PFS), respectively.
Results
A total of 108 patients were identified. With a median follow-up of 16.10 months median OS was 59.70 months for Hb ≥12.5g/dL vs. 14.13 months for Hb <12.5g/dL (p=0.004). PFS was 12.29 months for Hb ≥12.5g/dL and 1.68 months for Hb <12.5g/dL (p=0.016).
Conclusions
In this analysis, Hb ≥12.5g/dL correlated with significantly better OS and PFS. Further studies are needed to validate these findings.
Abstract
Aim
Evaluate pretreatment hemoglobin values as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy.
Background
Anemia is one of the most prevalent laboratory abnormalities in oncological disease. It leads to a decrease in cellular oxygen supply, altering radiosensitivity of tumor cells and compromising therapeutic outcomes.
Materials and Methods
Retrospective evaluation of patients with HNSCC treated with cCRT. Primary and secondary endpoint was to evaluate the correlation of Hb levels (≥12.5g/dL or <12.5g/dL) at the beginning of cCRT with overall survival (OS) and progression-free survival (PFS), respectively.
Results
A total of 108 patients were identified. With a median follow-up of 16.10 months median OS was 59.70 months for Hb ≥12.5g/dL vs. 14.13 months for Hb <12.5g/dL (p=0.004). PFS was 12.29 months for Hb ≥12.5g/dL and 1.68 months for Hb <12.5g/dL (p=0.016).
Conclusions
In this analysis, Hb ≥12.5g/dL correlated with significantly better OS and PFS. Further studies are needed to validate these findings.
Keywords
Hemoglobin; Anemia; Biomarkers; Head and neck neoplasms; Chemoradiotherapy
About this articleTitle
Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma
Journal
Reports of Practical Oncology and Radiotherapy
Issue
Pages
768-774
Published online
2020-09-01
DOI
10.1016/j.rpor.2020.07.002
Bibliographic record
Rep Pract Oncol Radiother 2020;25(5):768-774.
Keywords
Hemoglobin
Anemia
Biomarkers
Head and neck neoplasms
Chemoradiotherapy
Authors
Cecília Melo-Alvim
Patrícia Miguel-Semedo
Rita Silva Paiva
Soraia Lobo-Martins
Helena Luna-Pais
Ana Lúcia Costa
Ana Rita Santos
André Florindo
Ana Luísa Vasconcelos
André N. Abrunhosa-Branquinho
Paulo Palmela
Leonor Fernandes
Dolores Lopez Presa
Luís Costa
Leonor Ribeiro